GlassScriptPhysician profile
Sharina Robinson
NPI 1952817124
$1,886.02
in general payments reported to CMS, 2019-2025
15 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $264 · 2023: $148 · 2024: $252 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $262.55 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.19 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $237.78 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $225.36 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $194.66 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $161.82 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $101.81 | 2021-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $99.54 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $93.92 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $85.13 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $56.25 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $34.78 | 2022-2023 | Subvenite, Lamotrigine |
| E.R. Squibb & Sons, L.L.C. | $26.51 | 2025 | Cobenfy |
| Alkermes, INC. | $22.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharina Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.